AbbVie Inc. (NYSE: ABBV ) seems to have bucked the trend of health care weakness quite well. In the below chart, you can see that the stock has advanced around 18% YTD. Furthermore, AbbVie has fully recovered from Liberation DayI'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamma Sigma International Business Honor Society. My core values are: Excellence, Integrity ...

SAN JOSE, Calif., Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8th – 10th, 2025 at the Lotte New York Palace Hotel in New York City.Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings du ...

AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City. Rick Barry, President and Chief Executive Officer, will ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, PortugalDATE: August 30 – September ...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TS ...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TS ...

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: Ne ...

Company Overview - Protalix BioTherapeutics (PLX) is a commercial-stage biotech company focused on recombinant therapeutic proteins [1] - The company utilizes its proprietary plant cell-based ProCellEx technology [1] Product Portfolio - Protalix has two approved enzyme replacement therapies: 1) Elfabrio for Fabry disease 2) Elelyso for Gaucher disease [1]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **Chinese stock market** and its impact on the economy, particularly amid a growth slowdown and recent market rally since September 2024 [1][2][4]. Core Insights and Arguments 1. **Stock Market Rally Drivers**: - The Wind All A-Share Index surged by **56%** and the Hang Seng Index by **40%** since their lows in September 2024, driven by solid fundamentals, policy pivots, and a resurgence in biopharma [2][4]. - The rally is characterized by increased retail investor enthusiasm, with **6.8 million** new brokerage accounts opened in October 2024, the largest monthly increase since June 2015 [27][30]. 2. **Economic Fundamentals Weakening**: - Despite the stock market rally, economic fundamentals are expected to weaken in H2 2025 due to new austerity measures affecting mid-tier restaurants and alcohol sales, a payback effect from strong durable goods sales, and a slowdown in export growth [3][37]. - July activity data showed a decline in industrial production and retail sales growth, with industrial production dropping to **5.7%** y-o-y and retail sales to **3.7%** y-o-y [38]. 3. **Limited Boost to Real Economy**: - Historical lessons from the 2015 stock market crash suggest that the current rally may provide limited support to the real economy, with potential crowding out of big-item consumption and capital expenditure [4][61]. - The wealth effect from the stock market boom may not translate into increased consumption due to shifts in investment focus [4][61]. 4. **Beijing's Policy Strategy**: - Beijing faces a dilemma: rolling out pro-growth measures could inflate a stock market bubble, while inaction could worsen the growth slowdown. A cautious approach is recommended, avoiding high-profile monetary measures while addressing deep-rooted issues like the social security system [5][62]. - Future stimulus measures may include a **10bp cut in policy rates** and a **50bp cut in the reserve requirement ratio (RRR)** in Q4 2025, though timing remains uncertain [6][64]. 5. **Property Sector Challenges**: - The property sector continues to struggle, with new home sales and prices declining. The presales system has created a "bank run" scenario for developers, necessitating direct fiscal support from the government [65][66]. - Addressing the property sector's debt overhang is critical, with recommendations for the government to act as a "builder of last resort" to stabilize the market [67]. Other Important Insights - **AI and Biopharma as Growth Drivers**: The emergence of AI technologies, particularly the DeepSeek model, and a surge in biopharma innovations have been pivotal in driving market optimism [10][15]. - **US-China Relations**: Improved perceptions of US-China relations, particularly regarding tariffs and trade negotiations, have contributed to positive market sentiment [19][20]. - **Investor Sentiment**: The role of government media in shaping investor sentiment has been significant, with past comments contributing to market bubbles [60]. This summary encapsulates the key points discussed in the conference call, highlighting the interplay between the stock market, economic fundamentals, and policy responses in China.

Core Viewpoint - Iovance Biotherapeutics, despite its innovative drug Amtagvi for advanced melanoma, faces challenges in stock performance and operational execution [1][2]. Company Overview - Iovance Biotherapeutics is a small-cap biotech company known for developing Amtagvi, the first approved treatment for advanced melanoma [1]. - The manufacturing and administration process of Amtagvi is complex, requiring tumor samples from patients to extract T cells for lab growth, followed by patient-specific infusions [4]. Financial Performance - In Q2, Iovance reported approximately $60 million in revenue, nearly double from the previous year, primarily driven by Amtagvi sales [6]. - For fiscal 2025, the company anticipates total product revenue between $250 million and $300 million, predominantly from Amtagvi [6]. Market Potential - Amtagvi is expected to gain approval in additional regions, including Canada and Europe, within the next 12 months, potentially expanding the market significantly [7]. - The U.S. market for Amtagvi remains largely untapped, with only over 100 patients treated compared to the 8,000 annual melanoma deaths [8]. - There are opportunities for label expansions into other cancer indications, which could further increase the target market for Amtagvi [9]. Challenges - The complex and costly nature of Amtagvi poses challenges for Iovance in achieving profitability and market traction [10]. - The company ended Q2 with approximately $307 million in cash, which is projected to last until Q4 of the following year, indicating potential financial strain [11]. - Clinical and regulatory hurdles could negatively impact the stock price and overall company performance [12].